Folate-decorated lipid nanoparticles increased oral bioavailability of an ACE-inhibiting peptide by 30.7-fold and maintained blood pressure lowering for 6 days in rats.
30.7x bioavailabilityFolate-lipid nanoparticles increased oral peptide absorption 30.71-fold over free peptide in rats
What the researchers found
FA-VP5-LNPs achieved 30.71-fold higher oral bioavailability (AUC0-72h) than free VP5 peptide and sustained antihypertensive effects for 6 days.
Why it matters
Oral peptide delivery is a major pharmaceutical challenge. A 30-fold bioavailability improvement with sustained 6-day activity could transform how peptide drugs are administered.
The numbers in context
30.71x bioavailability improvement; 6-day antihypertensive effect; folate-PLGA-lipid nanoparticles; no toxicity
How the study worked
Nanoparticle formulation (PLGA core + folate-lipid shell), in vitro release studies, Caco-2/HT29 cell uptake, in situ rat intestinal absorption, in vivo pharmacokinetics, and blood pressure monitoring in rat hypertension model.
Who was studied
SD rats (in vivo); Caco-2 and HT29 cells (in vitro)
What this study cannot tell us
Rat study with unspecified group sizes; folate receptor expression varies between species; long-term safety and manufacturing scalability not assessed; only one peptide tested.
How to read the evidence
Moderate — comprehensive preclinical study with PK, PD, and safety data, but in rats only with unspecified group sizes.
When this study was published
Published in 2020; oral peptide delivery technology continues to advance rapidly.
The bigger picture
Most peptide drugs require injection because they're destroyed in the gut. Nanoparticle delivery systems like this could enable oral versions of many injectable peptide therapies beyond just blood pressure.
Questions still open
- Could this nanoparticle platform deliver other therapeutic peptides orally (GLP-1, insulin)?
- How does the folate-targeting mechanism work in human intestinal epithelium?
- What is the manufacturing cost compared to conventional ACE inhibitor pills?
Common questions
Why can't you just swallow peptide drugs?
How does folate help?
Read the original research
An efficient controlled release strategy for hypertension therapy: Folate-mediated lipid nanoparticles for oral peptide delivery.
Pharmacological research, 157, 104796
Citation
Li, Jinhua; Chen, Bin; Yu, Ting; Guo, Mengran; Zhao, Shengnan; Zhang, Yi; Jin, Chaohui; Peng, Xingchen; Zeng, Jun; Yang, Jian; Song, Xiangrong. (2020). An efficient controlled release strategy for hypertension therapy: Folate-mediated lipid nanoparticles for oral peptide delivery.. Pharmacological research, 157, 104796. https://doi.org/10.1016/j.phrs.2020.104796